Canada Markets close in 1 hr 34 mins

Advanced Proteome Therapeutics Corporation (APC.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.22500.0000 (0.00%)
As of 12:39PM EDT. Market open.
Full screen
Previous Close0.2250
Open0.2250
Bid0.2250 x 0
Ask0.2400 x 0
Day's Range0.2250 - 0.2250
52 Week Range0.0800 - 0.5100
Volume3,255
Avg. Volume28,209
Market Cap8.404M
Beta (5Y Monthly)0.49
PE Ratio (TTM)N/A
EPS (TTM)-0.0300
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Advanced Proteome Therapeutics Technology Featured in Oral Presentation at the World Molecular Imaging Congress

    Vancouver, British Columbia--(Newsfile Corp. - October 4, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company"), is pleased to announce that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI") will have its technology featured in an oral presentation at the World Molecular Imaging Congress.As previously announced, APTI and the Zeglis lab at the City University of New York, are pursuing a collaboration to investigate APTI's site-selective c

  • Newsfile

    Advanced Proteome Therapeutics Provides Update on COVID Program

    Burnaby, British Columbia--(Newsfile Corp. - August 24, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company"), reports that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI"), is dedicating additional resources to its SARS-CoV-2 protease inhibitor program.As previously announced, APTI's scientists identified multiple compounds with high predicted affinity for the main SARS-CoV-2 protease by in silico modeling and synthetic efforts and pre

  • Newsfile

    Advanced Proteome Therapeutics Announces Appointment of Dr. Benjamin Krantz to CEO

    Burnaby, British Columbia--(Newsfile Corp. - July 21, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company") is pleased to announce that as previously planned, Dr. Benjamin Krantz has taken over the role of CEO at its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI").Prior to this appointment, Benjamin Krantz MD, MBA was the Chief Fellow in hematology/oncology at New York University Langone Medical Center and served on the Board of Directors